USANA Health Sciences (NYSE:USNA) Updates FY 2024 Earnings Guidance

USANA Health Sciences (NYSE:USNA - Get Free Report) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 2.450-2.450 for the period, compared to the consensus earnings per share estimate of 2.500. The company issued revenue guidance of $850.0 million-$850.0 million, compared to the consensus revenue estimate of $861.9 million.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on USNA. DA Davidson decreased their price target on shares of USANA Health Sciences from $46.00 to $38.00 and set a "neutral" rating on the stock in a report on Thursday, July 25th. StockNews.com lowered USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, July 24th.

USANA Health Sciences Stock Performance

USANA Health Sciences stock traded down $0.55 during mid-day trading on Tuesday, hitting $34.50. 118,077 shares of the company traded hands, compared to its average volume of 79,924. USANA Health Sciences has a one year low of $34.15 and a one year high of $56.02. The stock has a market cap of $657.26 million, a price-to-earnings ratio of 10.75, a price-to-earnings-growth ratio of 1.20 and a beta of 0.89. The stock has a fifty day moving average price of $38.02 and a 200-day moving average price of $42.59.

USANA Health Sciences (NYSE:USNA - Get Free Report) last posted its quarterly earnings data on Tuesday, July 23rd. The company reported $0.54 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.65 by ($0.11). USANA Health Sciences had a return on equity of 11.13% and a net margin of 6.29%. The company had revenue of $212.87 million for the quarter, compared to the consensus estimate of $218.64 million. During the same period in the prior year, the firm posted $0.89 earnings per share. Sell-side analysts predict that USANA Health Sciences will post 2.5 EPS for the current year.

Insider Buying and Selling at USANA Health Sciences

In other USANA Health Sciences news, insider Paul A. Jones sold 6,266 shares of the company's stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $38.38, for a total value of $240,489.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, Director Gilbert A. Fuller sold 674 shares of the firm's stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $39.69, for a total transaction of $26,751.06. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Paul A. Jones sold 6,266 shares of USANA Health Sciences stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $38.38, for a total value of $240,489.08. The disclosure for this sale can be found here. Insiders have sold 7,940 shares of company stock worth $311,670 over the last 90 days. Corporate insiders own 0.33% of the company's stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.